Drug Profile
Research programme: encapsulated cellular cancer immunotherapeutics - MaxiVax
Alternative Names: Encapsulated cellular cancer immunotherapy - MaxiVaxLatest Information Update: 28 Mar 2020
Price :
$50
*
At a glance
- Originator MaxiVax
- Class Cancer vaccines; Cell therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for research development in Cancer in Switzerland (Parenteral)
- 09 Feb 2016 Early research in Cancer in Switzerland (Parenteral)